Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Edwards Lifesciences CorpEW · Entity 3026 | CVP, Critical Care | September 03, 2024 | September 03, 2024 |
| Outset Medical, Inc.OM · Entity 7026 | Director | May 31, 2023 | May 31, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Edwards Lifesciences Corp
Report date September 03, 2024 · Filed September 03, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 81,287.4373 |
Ending reported balance
After 2024-09-03 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2024-09-03 · Grant · Acquired 10,910 · Balance 86,817.4373 F1: These restricted stock units were granted on September 3, 2024 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are 100% vested and exercisable on the grant date. Row 2 · 2024-09-03 · Tax withholding · Disposed 5,530 · Balance 81,287.4373 |
Filing footnotes · ownership attribution and instrument terms
F1: These restricted stock units were granted on September 3, 2024 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are 100% vested and exercisable on the grant date.
Outset Medical, Inc.
Report date May 31, 2023 · Filed May 31, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 24,596 |
Reported balance
After 2023-05-31 transaction · row 1
1 source rowRow 1 · 2023-05-31 · Grant · Acquired 7,681 · Balance 24,596 F1: 100% of the shares underlying these RSUs will vest upon the earlier of (i) the one-year anniversary of the date of grant or (ii) the date of the Issuer's next Annual Meeting of Stockholders |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of the shares underlying these RSUs will vest upon the earlier of (i) the one-year anniversary of the date of grant or (ii) the date of the Issuer's next Annual Meeting of Stockholders
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Inari Medical, Inc.
Report date February 19, 2025 · Filed February 19, 2025
Section 16 reporting ended · disclosed 2025-02-19. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-02-19 transaction · row 1
1 source rowRow 1 · 2025-02-19 · Other · Disposed 22,429 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated January 6, 2025, by and among Stryker Corporation ("Parent"), Eagle 1 Merger Sub, Inc. ("Merger Sub"), and Inari Medical, Inc. ("Issuer") on February 19, 2025 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock of the Issuer ("Common Stock") was cancelled and converted into the right to receive $80.00 in cash (the "Merger Consideration"), without interest. F2: Includes 4,126 restricted stock units ("RSUs"). At the Effective Time, each outstanding award of RSUs was canceled and converted into the right to receive an amount in cash equal to the product of the aggregate number of shares of Common Stock underlying such RSU immediately prior to the Effective Time, multiplied by the Merger Consideration. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $5.73 | Direct | 0 |
Reported balance
After 2025-02-19 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-02-19 · Disposition to issuer · Disposed 49,719 · Balance 0 F3: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of shares of Common Stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated January 6, 2025, by and among Stryker Corporation ("Parent"), Eagle 1 Merger Sub, Inc. ("Merger Sub"), and Inari Medical, Inc. ("Issuer") on February 19, 2025 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock of the Issuer ("Common Stock") was cancelled and converted into the right to receive $80.00 in cash (the "Merger Consideration"), without interest.
F2: Includes 4,126 restricted stock units ("RSUs"). At the Effective Time, each outstanding award of RSUs was canceled and converted into the right to receive an amount in cash equal to the product of the aggregate number of shares of Common Stock underlying such RSU immediately prior to the Effective Time, multiplied by the Merger Consideration.
F3: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of shares of Common Stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement.
MASIMO CORP
Report date June 10, 2026 · Filed June 12, 2026
Section 16 reporting ended · disclosed 2026-06-12. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-06-10 transaction · row 1
1 source rowRow 1 · 2026-06-10 · Disposition to issuer · Disposed 7,605 · Balance 0 F1: On June 10, 2026, pursuant to the Agreement and Plan of Merger, dated February 16, 2026, by and among Masimo Corporation (the "Issuer"), Danaher Corporation ("Parent"), and Mobius Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). F2: On June 10, 2026, at the effective time of the Merger, each share of the Issuer's common stock, par value $0.001 per share (the "Common Stock") issued and outstanding prior to the effective time of the Merger (other than certain excluded shares and dissenting shares) was canceled, extinguished and converted into the right to receive an amount in cash equal to $180.00 per share, without interest (the "Per Share Merger Consideration"). |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-06-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-10 · Disposition to issuer · Disposed 22,283 · Balance 0 F4: Represents the unvested portion of RSUs granted on February 12, 2025, which award of RSUs was to vest ratably over three years. F3: On June 10, 2026, at the effective time of the Merger, each of the Issuer's restricted stock units ("RSUs") (other than certain RSUs held by the Issuer's non-employee directors) was assumed by Parent and converted into a number of RSUs of Parent equal to the product of the number of shares of Parent common stock equal to the number of shares of Common Stock underlying such RSU multiplied by the quotient of (a) the Per Share Merger Consideration, divided by (b) the volume-weighted average trading price per share of Parent's common stock for the ten trading day period ending on and including June 10, 2026 ($183.33). F1: On June 10, 2026, pursuant to the Agreement and Plan of Merger, dated February 16, 2026, by and among Masimo Corporation (the "Issuer"), Danaher Corporation ("Parent"), and Mobius Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-06-10 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-10 · Disposition to issuer · Disposed 6,306 · Balance 0 F5: Represents the unvested portion of RSUs granted on March 11, 2025, which award of RSUs was to vest ratably over four years. F3: On June 10, 2026, at the effective time of the Merger, each of the Issuer's restricted stock units ("RSUs") (other than certain RSUs held by the Issuer's non-employee directors) was assumed by Parent and converted into a number of RSUs of Parent equal to the product of the number of shares of Parent common stock equal to the number of shares of Common Stock underlying such RSU multiplied by the quotient of (a) the Per Share Merger Consideration, divided by (b) the volume-weighted average trading price per share of Parent's common stock for the ten trading day period ending on and including June 10, 2026 ($183.33). F1: On June 10, 2026, pursuant to the Agreement and Plan of Merger, dated February 16, 2026, by and among Masimo Corporation (the "Issuer"), Danaher Corporation ("Parent"), and Mobius Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-06-10 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-06-10 · Disposition to issuer · Disposed 39,904 · Balance 0 F6: Represents the unvested portion of RSUs granted on March 6, 2026, which award of RSUs was to vest ratably over four years. F3: On June 10, 2026, at the effective time of the Merger, each of the Issuer's restricted stock units ("RSUs") (other than certain RSUs held by the Issuer's non-employee directors) was assumed by Parent and converted into a number of RSUs of Parent equal to the product of the number of shares of Parent common stock equal to the number of shares of Common Stock underlying such RSU multiplied by the quotient of (a) the Per Share Merger Consideration, divided by (b) the volume-weighted average trading price per share of Parent's common stock for the ten trading day period ending on and including June 10, 2026 ($183.33). F1: On June 10, 2026, pursuant to the Agreement and Plan of Merger, dated February 16, 2026, by and among Masimo Corporation (the "Issuer"), Danaher Corporation ("Parent"), and Mobius Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). |
| Non-Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $166.52 | Direct | 0 |
Reported balance
After 2026-06-10 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-06-10 · Disposition to issuer · Disposed 18,617 · Balance 0 F7: On June 10, 2026, at the effective time of the Merger, each of the Issuer's stock options outstanding as of immediately prior to the effective time of the Merger, whether vested or unvested, were canceled and converted into the right to receive, for each share of Common Stock subject to such option, the excess, if any, of the Per Share Merger Consideration over the exercise price per share of such option, without interest and less any applicable tax withholding. F1: On June 10, 2026, pursuant to the Agreement and Plan of Merger, dated February 16, 2026, by and among Masimo Corporation (the "Issuer"), Danaher Corporation ("Parent"), and Mobius Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). |
| Performance-Based Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-06-10 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-06-10 · Disposition to issuer · Disposed 49,243 · Balance 0 F9: Represents the PSUs granted on March 11, 2025, which represented the right to receive shares of Common Stock over a three year performance period, determined at target performance. F8: On June 10, 2026, at the effective time of the Merger, each of the Issuer's performance-based restricted stock units ("PSUs") outstanding as of immediately prior to the effective time of the Merger, as determined at target performance, were canceled and converted into the right to receive $180.00 for each share of Common Stock underlying such award of PSUs, without interest and less any applicable tax withholding. F1: On June 10, 2026, pursuant to the Agreement and Plan of Merger, dated February 16, 2026, by and among Masimo Corporation (the "Issuer"), Danaher Corporation ("Parent"), and Mobius Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). |
Filing footnotes · ownership attribution and instrument terms
F1: On June 10, 2026, pursuant to the Agreement and Plan of Merger, dated February 16, 2026, by and among Masimo Corporation (the "Issuer"), Danaher Corporation ("Parent"), and Mobius Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger").
F2: On June 10, 2026, at the effective time of the Merger, each share of the Issuer's common stock, par value $0.001 per share (the "Common Stock") issued and outstanding prior to the effective time of the Merger (other than certain excluded shares and dissenting shares) was canceled, extinguished and converted into the right to receive an amount in cash equal to $180.00 per share, without interest (the "Per Share Merger Consideration").
F3: On June 10, 2026, at the effective time of the Merger, each of the Issuer's restricted stock units ("RSUs") (other than certain RSUs held by the Issuer's non-employee directors) was assumed by Parent and converted into a number of RSUs of Parent equal to the product of the number of shares of Parent common stock equal to the number of shares of Common Stock underlying such RSU multiplied by the quotient of (a) the Per Share Merger Consideration, divided by (b) the volume-weighted average trading price per share of Parent's common stock for the ten trading day period ending on and including June 10, 2026 ($183.33).
F4: Represents the unvested portion of RSUs granted on February 12, 2025, which award of RSUs was to vest ratably over three years.
F5: Represents the unvested portion of RSUs granted on March 11, 2025, which award of RSUs was to vest ratably over four years.
F6: Represents the unvested portion of RSUs granted on March 6, 2026, which award of RSUs was to vest ratably over four years.
F7: On June 10, 2026, at the effective time of the Merger, each of the Issuer's stock options outstanding as of immediately prior to the effective time of the Merger, whether vested or unvested, were canceled and converted into the right to receive, for each share of Common Stock subject to such option, the excess, if any, of the Per Share Merger Consideration over the exercise price per share of such option, without interest and less any applicable tax withholding.
F8: On June 10, 2026, at the effective time of the Merger, each of the Issuer's performance-based restricted stock units ("PSUs") outstanding as of immediately prior to the effective time of the Merger, as determined at target performance, were canceled and converted into the right to receive $180.00 for each share of Common Stock underlying such award of PSUs, without interest and less any applicable tax withholding.
F9: Represents the PSUs granted on March 11, 2025, which represented the right to receive shares of Common Stock over a three year performance period, determined at target performance.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 16, 2021 Filed Feb 17, 2021 00:40 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 3,389 | $22.29 | $75,529.63 |
DisclosureSEC source: 0001225208-21-002568 · doc4.xml · nonDerivative · entry 1 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,135.1397 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 24, 2020. Read SEC document |
| January 15, 2021 Filed Jan 16, 2021 02:49 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 3,389 | $0.00 Strike: $22.29 | $0.00 |
DisclosureSEC source: 0001225208-21-000866 · doc4.xml · derivative · entry 3 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,966 Underlying: Common Stock · 3,389 shares Expires 2022-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 15, 2021 Filed Jan 16, 2021 02:49 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 3,389 | $87.27 | $295,758.03 |
DisclosureSEC source: 0001225208-21-000866 · doc4.xml · nonDerivative · entry 2 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,746.1397 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 24, 2020. Read SEC document |
| January 15, 2021 Filed Jan 16, 2021 02:49 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 3,389 | $22.29 | $75,529.63 |
DisclosureSEC source: 0001225208-21-000866 · doc4.xml · nonDerivative · entry 1 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,135.1397 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 24, 2020. Read SEC document |
| October 29, 2020 Filed Oct 30, 2020 00:50 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 20,355 | $0.00 Strike: $22.29 | $0.00 |
DisclosureSEC source: 0001225208-20-012815 · doc4.xml · derivative · entry 3 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,355 Underlying: Common Stock · 20,355 shares Expires 2022-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 29, 2020 Filed Oct 30, 2020 00:50 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 20,355 | $73.24 | $1,490,883.66 |
DisclosureSEC source: 0001225208-20-012815 · doc4.xml · nonDerivative · entry 2 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,746.1397 F1 · price: This transaction was executed in multiple trades at prices ranging from $72.9800 to $73.4300. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 29, 2020 Filed Oct 30, 2020 00:50 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 20,355 | $22.29 | $453,645.78 |
DisclosureSEC source: 0001225208-20-012815 · doc4.xml · nonDerivative · entry 1 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,101.1397 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 13, 2020 Filed Aug 13, 2020 23:21 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 2,249 | $78.24 | $175,961.76 |
DisclosureSEC source: 0001225208-20-010598 · doc4.xml · nonDerivative · entry 1 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,746.1397 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 28, 2020. Read SEC document |
| July 14, 2020 Filed Jul 14, 2020 20:37 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 2,249 | $67.66 | $152,167.34 |
DisclosureSEC source: 0001225208-20-009740 · doc4.xml · nonDerivative · entry 1 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,995.1397 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 28, 2020. Read SEC document |
| June 16, 2020 Filed Jun 16, 2020 20:18 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 3,348 | $70.67 | $236,603.16 |
DisclosureSEC source: 0001225208-20-009021 · doc4.xml · nonDerivative · entry 1 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,215.6694 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 28, 2020. Read SEC document |
| June 11, 2020 Filed Jun 11, 2020 22:54 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 2,249 | $72.59 | $163,254.91 |
DisclosureSEC source: 0001225208-20-008853 · doc4.xml · nonDerivative · entry 1 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,563.6694 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 28, 2020. Read SEC document |
| May 27, 2020 Filed May 27, 2020 18:40 UTC | Inari Medical, Inc. NARI · Entity 83035 | PurchaseCommon Stock | 28,091 | $19.00 | $533,729.00 |
DisclosureSEC source: 0001209191-20-032418 · doc4.xml · nonDerivative · entry 1 Szyman Catherine M. · CIK 0001438538 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,091 Read SEC document |
| May 14, 2020 Filed May 14, 2020 20:12 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 1,116 | $212.69 | $237,362.04 |
DisclosureSEC source: 0001225208-20-007661 · doc4.xml · nonDerivative · entry 1 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,270.8898 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 28, 2020. Read SEC document |
| May 13, 2020 Filed May 13, 2020 22:28 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 750 | $216.93 | $162,697.50 |
DisclosureSEC source: 0001225208-20-007628 · doc4.xml · nonDerivative · entry 5 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,386.8898 F2 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 28, 2020. Read SEC document |
| May 12, 2020 Filed May 13, 2020 22:28 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 682 | $225.05 | $153,484.10 |
DisclosureSEC source: 0001225208-20-007628 · doc4.xml · nonDerivative · entry 4 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,136.8898 Read SEC document |
| May 11, 2020 Filed May 13, 2020 22:28 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionPerformance Rights · Derivative | 5,950 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-007628 · doc4.xml · derivative · entry 6 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,950 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On May 11, 2017, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 6, 2020, the Compensation Committee of the Board of Directors determined that 175% of the target shares would vest as of May 11, 2020, and the actual number of shares vested are reflected on this Form. F1 · derivative.exercise_date: On May 11, 2017, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 6, 2020, the Compensation Committee of the Board of Directors determined that 175% of the target shares would vest as of May 11, 2020, and the actual number of shares vested are reflected on this Form. F1 · derivative.expiration_date: On May 11, 2017, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 6, 2020, the Compensation Committee of the Board of Directors determined that 175% of the target shares would vest as of May 11, 2020, and the actual number of shares vested are reflected on this Form. F1 · derivative.underlying_shares: On May 11, 2017, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 6, 2020, the Compensation Committee of the Board of Directors determined that 175% of the target shares would vest as of May 11, 2020, and the actual number of shares vested are reflected on this Form. Read SEC document |
| May 11, 2020 Filed May 13, 2020 22:28 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 2,951 | $217.84 | $642,845.84 |
DisclosureSEC source: 0001225208-20-007628 · doc4.xml · nonDerivative · entry 3 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,818.8898 Read SEC document |
| May 11, 2020 Filed May 13, 2020 22:28 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 548 | $217.84 | $119,376.32 |
DisclosureSEC source: 0001225208-20-007628 · doc4.xml · nonDerivative · entry 2 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,769.8898 Read SEC document |
| May 11, 2020 Filed May 13, 2020 22:28 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 5,950 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-007628 · doc4.xml · nonDerivative · entry 1 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,317.8898 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On May 11, 2017, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 6, 2020, the Compensation Committee of the Board of Directors determined that 175% of the target shares would vest as of May 11, 2020, and the actual number of shares vested are reflected on this Form. F1 · price: On May 11, 2017, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 6, 2020, the Compensation Committee of the Board of Directors determined that 175% of the target shares would vest as of May 11, 2020, and the actual number of shares vested are reflected on this Form. Read SEC document |
| May 07, 2020 Filed May 8, 2020 23:27 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantPerformance Rights · Derivative | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-007339 · doc4.xml · derivative · entry 3 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Underlying: Common Stock · 2,000 shares Expires 2027-05-06 F3 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 7, 2020 and scheduled to vest on May 7, 2023. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. F3 · shares: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 7, 2020 and scheduled to vest on May 7, 2023. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. F3 · derivative.exercise_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 7, 2020 and scheduled to vest on May 7, 2023. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. F3 · derivative.expiration_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 7, 2020 and scheduled to vest on May 7, 2023. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. F3 · derivative.underlying_shares: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 7, 2020 and scheduled to vest on May 7, 2023. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. Read SEC document |
| May 07, 2020 Filed May 8, 2020 23:27 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantEmployee Stock Option (Right to Acquire) · Derivative | 14,600 | $0.00 Strike: $218.40 | $0.00 |
DisclosureSEC source: 0001225208-20-007339 · doc4.xml · derivative · entry 2 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,600 Underlying: Common Stock · 14,600 shares Expires 2027-05-06 F2 · derivative.exercise_date: These options were granted on May 7, 2020 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| May 07, 2020 Filed May 8, 2020 23:27 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantCommon Stock | 1,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-007339 · doc4.xml · nonDerivative · entry 1 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,367.8898 F1 · shares: These restricted stock units were granted on May 7, 2020 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| April 30, 2020 Filed Apr 30, 2020 22:56 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GiftCommon Stock | 3,987 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-006929 · doc4.xml · nonDerivative · entry 1 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,767.8898 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 28, 2020. Read SEC document |
| April 16, 2020 Filed Apr 16, 2020 20:25 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 1,116 | $216.91 | $242,071.56 |
DisclosureSEC source: 0001225208-20-006509 · doc4.xml · nonDerivative · entry 1 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,754.8898 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 28, 2020. Read SEC document |
| March 23, 2020 Filed Mar 23, 2020 21:36 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 1,116 | $162.95 | $181,852.20 |
DisclosureSEC source: 0001225208-20-005482 · doc4.xml · nonDerivative · entry 1 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,773.2167 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 28, 2020. Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 01:16 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 2,500 | $0.00 Strike: $66.86 | $0.00 |
DisclosureSEC source: 0001225208-20-002681 · doc4.xml · derivative · entry 3 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,570 Underlying: Common Stock · 2,500 shares Expires 2022-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 20, 2019. Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 01:16 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 2,500 | $228.57 | $571,425.00 |
DisclosureSEC source: 0001225208-20-002681 · doc4.xml · nonDerivative · entry 2 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,889.2167 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 20, 2019. Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 01:16 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 2,500 | $66.86 | $167,150.00 |
DisclosureSEC source: 0001225208-20-002681 · doc4.xml · nonDerivative · entry 1 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,389.2167 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 20, 2019. Read SEC document |
| February 03, 2020 Filed Feb 4, 2020 01:56 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 2,500 | $0.00 Strike: $66.86 | $0.00 |
DisclosureSEC source: 0001225208-20-001530 · doc4.xml · derivative · entry 3 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,070 Underlying: Common Stock · 2,500 shares Expires 2022-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 20, 2019. Read SEC document |
| February 03, 2020 Filed Feb 4, 2020 01:56 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 2,500 | $219.50 | $548,750.00 |
DisclosureSEC source: 0001225208-20-001530 · doc4.xml · nonDerivative · entry 2 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,889.2167 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 20, 2019. Read SEC document |
| February 03, 2020 Filed Feb 4, 2020 01:56 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 2,500 | $66.86 | $167,150.00 |
DisclosureSEC source: 0001225208-20-001530 · doc4.xml · nonDerivative · entry 1 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,389.2167 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 20, 2019. Read SEC document |
| January 03, 2020 Filed Jan 4, 2020 00:22 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GiftCommon Stock | 221.8071 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-000377 · doc4.xml · nonDerivative · entry 1 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,889.2167 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 20, 2019. Read SEC document |
| December 16, 2019 Filed Dec 16, 2019 21:17 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 2,500 | $0.00 Strike: $66.86 | $0.00 |
DisclosureSEC source: 0001225208-19-015846 · doc4.xml · derivative · entry 3 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,570 Underlying: Common Stock · 2,500 shares Expires 2022-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 20, 2019. Read SEC document |
| December 16, 2019 Filed Dec 16, 2019 21:17 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 2,500 | $234.27 | $585,686.50 |
DisclosureSEC source: 0001225208-19-015846 · doc4.xml · nonDerivative · entry 2 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,104.8134 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 20, 2019. Read SEC document |
| December 16, 2019 Filed Dec 16, 2019 21:17 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 2,500 | $66.86 | $167,150.00 |
DisclosureSEC source: 0001225208-19-015846 · doc4.xml · nonDerivative · entry 1 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,604.8134 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 20, 2019. Read SEC document |
| November 15, 2019 Filed Nov 16, 2019 01:33 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 2,500 | $0.00 Strike: $66.86 | $0.00 |
DisclosureSEC source: 0001225208-19-014593 · doc4.xml · derivative · entry 3 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,070 Underlying: Common Stock · 2,500 shares Expires 2022-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 20, 2019. Read SEC document |
| November 15, 2019 Filed Nov 16, 2019 01:33 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 2,500 | $242.14 | $605,350.00 |
DisclosureSEC source: 0001225208-19-014593 · doc4.xml · nonDerivative · entry 2 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,104.8134 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 20, 2019. Read SEC document |
| November 15, 2019 Filed Nov 16, 2019 01:33 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 2,500 | $66.86 | $167,150.00 |
DisclosureSEC source: 0001225208-19-014593 · doc4.xml · nonDerivative · entry 1 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,604.8134 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 20, 2019. Read SEC document |
| October 25, 2019 Filed Oct 25, 2019 23:07 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 2,500 | $66.86 Strike: $66.86 | $167,150.00 |
DisclosureSEC source: 0001225208-19-013853 · doc4.xml · derivative · entry 3 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,570 Underlying: Common Stock · 2,500 shares Expires 2022-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 20, 2019. Read SEC document |
| October 25, 2019 Filed Oct 25, 2019 23:07 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 2,500 | $227.19 | $567,975.00 |
DisclosureSEC source: 0001225208-19-013853 · doc4.xml · nonDerivative · entry 2 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,104.8134 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 20, 2019. Read SEC document |
| October 25, 2019 Filed Oct 25, 2019 23:07 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 2,500 | $66.86 | $167,150.00 |
DisclosureSEC source: 0001225208-19-013853 · doc4.xml · nonDerivative · entry 1 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,604.8134 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 20, 2019. Read SEC document |
| September 19, 2019 Filed Sep 20, 2019 18:59 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 2,500 | $0.00 Strike: $66.86 | $0.00 |
DisclosureSEC source: 0001225208-19-012746 · doc4.xml · derivative · entry 4 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,070 Underlying: Common Stock · 2,500 shares Expires 2022-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 20, 2019. Read SEC document |
| September 19, 2019 Filed Sep 20, 2019 18:59 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GiftCommon Stock | 583.3446 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-012746 · doc4.xml · nonDerivative · entry 3 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,054.6972 Read SEC document |
| September 19, 2019 Filed Sep 20, 2019 18:59 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 2,500 | $216.71 | $541,775.00 |
DisclosureSEC source: 0001225208-19-012746 · doc4.xml · nonDerivative · entry 2 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,638.0418 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 20, 2019. Read SEC document |
| September 19, 2019 Filed Sep 20, 2019 18:59 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 2,500 | $66.86 | $167,150.00 |
DisclosureSEC source: 0001225208-19-012746 · doc4.xml · nonDerivative · entry 1 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,138.0418 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 20, 2019. Read SEC document |
| August 30, 2019 Filed Aug 30, 2019 21:02 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 334 | $222.00 | $74,148.00 |
DisclosureSEC source: 0001225208-19-011999 · doc4.xml · nonDerivative · entry 2 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 0 F2 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person's spouse on April 29, 2018. Read SEC document |
| August 30, 2019 Filed Aug 30, 2019 21:02 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 372 | $222.00 | $82,584.00 |
DisclosureSEC source: 0001225208-19-011999 · doc4.xml · nonDerivative · entry 1 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,638.0418 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 29, 2018. Read SEC document |
| August 15, 2019 Filed Aug 16, 2019 15:11 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 328 | $214.53 | $70,365.84 |
DisclosureSEC source: 0001225208-19-011471 · doc4.xml · nonDerivative · entry 2 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 334 F2 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person's spouse on August 29, 2018. Read SEC document |
| August 15, 2019 Filed Aug 16, 2019 15:11 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 372 | $214.53 | $79,805.16 |
DisclosureSEC source: 0001225208-19-011471 · doc4.xml · nonDerivative · entry 1 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,010.0418 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 29, 2018. Read SEC document |
| July 15, 2019 Filed Jul 15, 2019 20:53 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 328 | $191.70 | $62,877.60 |
DisclosureSEC source: 0001225208-19-010246 · doc4.xml · nonDerivative · entry 3 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 662 F2 · date: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person's spouse on August 29, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.